Q1 2026 · 13F-HR
Defilade Capital Management, L.P.holdings as filed
Filed 2026-05-14 · accession 0002088557-26-000005
$712.2M
Reported value
31
Positions
2026-03-31
Period end
The Brief · Defilade Capital Management, L.P. · Q1 2026
AI · grounded in 13F
Defilade Capital Management, L.P. closed its position in ABBV for a reduction of $52.02M. The fund established new positions in ZBH for $52.37M and PTCT for $41.11M. Other notable activity includes closing its stake in NVS for $50.02M and increasing its share count in INSM by 289.8%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 98956P102 | ZBH | ZIMMER BIOMET HOLDINGS INC | $52.4M | 7.35% | 579,161 | Common | SOLE |
| 806407102 | HSIC | SCHEIN HENRY INC | $46.0M | 6.46% | 624,037 | Common | SOLE |
| 075887109 | BDX | BECTON DICKINSON & CO | $43.9M | 6.16% | 279,210 | Common | SOLE |
| 69366J200 | PTCT | PTC THERAPEUTICS INC | $41.1M | 5.77% | 376,165 | Common | SOLE |
| 252131107 | DXCM | DEXCOM INC | $33.8M | 4.75% | 538,762 | Common | SOLE |
| 44930G107 | ICUI | ICU MED INC | $32.8M | 4.61% | 254,291 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $31.9M | 4.48% | 194,909 | Common | SOLE |
| 46120E602 | ISRG | INTUITIVE SURGICAL INC | $31.2M | 4.38% | 67,681 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $30.7M | 4.31% | 315,972 | Common | SOLE |
| 379577208 | GMED | GLOBUS MED INC | $30.5M | 4.29% | 354,350 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $27.7M | 3.88% | 209,932 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $26.1M | 3.67% | 1,359,969 | Common | SOLE |
| 69380Q107 | PACS | PACS GROUP INC | $25.6M | 3.60% | 604,180 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $22.4M | 3.15% | 1,504,536 | Common | SOLE |
| 28414H103 | ELAN | ELANCO ANIMAL HEALTH INC | $22.3M | 3.13% | 931,121 | Common | SOLE |
| 717081103 | PFE | PFIZER INC | $19.4M | 2.72% | 1,464,129 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $19.0M | 2.67% | 20,696 | Common | SOLE |
| 516544103 | LNTH | LANTHEUS HLDGS INC | $18.9M | 2.66% | 249,401 | Common | SOLE |
| 45826H109 | ITGR | INTEGER HLDGS CORP | $18.7M | 2.63% | 213,027 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $17.7M | 2.48% | 96,289 | Common | SOLE |
| 30054Y107 | EVMN | EVOMMUNE INC | $15.6M | 2.19% | 678,589 | Common | SOLE |
| 875372203 | TNDM | TANDEM DIABETES CARE INC | $14.6M | 2.05% | 761,905 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $13.6M | 1.91% | 352,590 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $13.3M | 1.87% | 129,950 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $12.6M | 1.77% | 1,487,645 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $11.9M | 1.67% | 51,895 | Common | SOLE |
| 016255101 | ALGN | ALIGN TECHNOLOGY INC | $11.5M | 1.62% | 67,332 | Common | SOLE |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $11.0M | 1.54% | 3,564,127 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $10.7M | 1.50% | 842,928 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $2.7M | 0.38% | 315,944 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $2.5M | 0.35% | 7,558,756 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.